Proposed Substances To Be Evaluated for Toxicological Profile Development, 32039-32040 [2020-11423]

Download as PDF Federal Register / Vol. 85, No. 103 / Thursday, May 28, 2020 / Notices (Authority: Pub. L. 92–463, § 1, Oct. 6, 1972, 86 Stat. 770) Dated: May 21, 2020. Mary Ross, Director, Office of Science Advisor, Policy, and Engagement. [FR Doc. 2020–11397 Filed 5–27–20; 8:45 am] BILLING CODE 6560–50–P Board of Governors of the Federal Reserve System, May 22, 2020. Yao-Chin Chao, Assistant Secretary of the Board. FEDERAL RESERVE SYSTEM jbell on DSKJLSW7X2PROD with NOTICES Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holding Company [FR Doc. 2020–11481 Filed 5–27–20; 8:45 am] BILLING CODE P The notificants listed below have applied under the Change in Bank Control Act (Act) (12 U.S.C. 1817(j)) and § 225.41 of the Board’s Regulation Y (12 CFR 225.41) to acquire shares of a bank or bank holding company. The factors that are considered in acting on the applications are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)). The applications listed below, as well as other related filings required by the Board, if any, are available for immediate inspection at the Federal Reserve Bank indicated. The applications will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in paragraph 7 of the Act. Comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Ann E. Misback, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington, DC 20551–0001, not later than June 11, 2020. A. Federal Reserve Bank of Minneapolis (Chris P. Wangen, Assistant Vice President), 90 Hennepin Avenue, Minneapolis, Minnesota 55480–0291: 1. The Bank Holding Company Stock Trust Agreement of Steven R. Krause and Rebecca R. Krause, Steven R. Krause and Rebecca R. Krause as cotrustees, and Andrew Krause, all of Winnebago, Minnesota; Erin Church, Canistota, South Dakota; and Emily Sebesta, Willmar, Minnesota; as members of the Krause Family Shareholder Group acting in concert to retain voting shares of Krause Financial, Inc., and thereby indirectly retain voting shares of First Financial Bank in Winnebago, both of Winnebago, Minnesota. B. Federal Reserve Bank of San Francisco (Sebastian Astrada, Director, Applications) 101 Market Street, San Francisco, California 94105–1579: VerDate Sep<11>2014 16:32 May 27, 2020 Jkt 250001 1. Megan F. Clubb and Clifford ‘‘Kip’’ W. Kontos, both of Walla Walla, Washington, and Charles H. Eglin, Yakima, Washington; as a group acting in concert to acquire voting shares of Baker Boyer Bancorp and thereby indirectly acquire Baker Boyer National Bank, both of Walla Walla, Washington. DEPARTMENT OF HEALTH AND HUMAN SERVICES Agency for Toxic Substances and Disease Registry [Docket No. ATSDR–2020–0002] Proposed Substances To Be Evaluated for Toxicological Profile Development Agency for Toxic Substances and Disease Registry (ATSDR), Department of Health and Human Services (HHS). ACTION: Request for comments on proposed substances to be evaluated for Toxicological Profile development. AGENCY: The Agency for Toxic Substances and Disease Registry (ATSDR) within the Department of Health and Human Services is initiating the development of another set of Toxicological Profiles. This notice solicits public nominations of substances for ATSDR to evaluate for Toxicological Profile development. ATSDR will consider nominations from the Substance Priority List (available at https://www.atsdr.cdc.gov/SPL/). ATSDR also accepts nominations for non-Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA) substances that may have public health implications, on the basis of ATSDR’s authority to prepare Toxicological Profiles for substances not found at sites on the CERCLA National Priorities List. For more information on the CERCLA National Priorities List, visit https:// www.epa.gov/superfund/ superfundnational-priorities-list-npl. The agency will do so in order to establish and maintain an inventory of literature, research, and studies on the health effects of toxic substances, to respond to requests for consultation, and to support the site-specific response actions conducted by ATSDR, as otherwise necessary. SUMMARY: PO 00000 Frm 00037 Fmt 4703 Sfmt 4703 32039 Nominations from the Substance Priority List and/or additional substances must be received by June 29, 2020. DATES: You may submit nominations, identified by Docket No. ATSDR–2020–0002, by any of the following methods: • Internet: Access the Federal eRulemaking portal at www.regulations.gov. Follow the instructions for submitting comments. • Mail: Division of Toxicology and Human Health Sciences, Agency for Toxic Substances and Disease Registry, 1600 Clifton Rd. NE, Mail Stop S102–1, Atlanta, GA, 30329–4027. Attn: Docket No. ATSDR–2020–0002. Instructions: All submissions must include the agency name and docket number for this notice. All relevant comments will be posted without change. This means that no confidential business information or other confidential information should be submitted in response to this notice. Refer to the section Submission of Nominations (below) for the specific information required. ADDRESSES: For further information, please contact Susan Ingber, Agency for Toxic Substances and Disease Registry, Division of Toxicology and Human Health Sciences, 1600 Clifton Rd. NE, Mail Stop S102–1, Atlanta, GA, 30329– 4027, Email: ATSDRToxProfileFRNs@ cdc.gov; Phone: 1–800–232–4636. FOR FURTHER INFORMATION CONTACT: The Superfund Amendments and Reauthorization Act of 1986 (SARA) [42 U.S.C. 9601 et seq.] amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund) [42 U.S.C. 9601 et seq.] by establishing certain requirements for ATSDR and the U.S. Environmental Protection Agency (EPA) with regard to hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) (for more information, visit https://www.epa.gov/ superfund/superfund-nationalprioritieslist-npl). Among these statutory requirements is a mandate for the Administrator of ATSDR to prepare Toxicological Profiles for each substance included on the Priority List of Hazardous Substances (also known as the Substance Priority list (SPL)). This list identifies 275 hazardous substances found at NPL sites that ATSDR and EPA have determined pose the most significant current potential threat to human health. SUPPLEMENTARY INFORMATION: E:\FR\FM\28MYN1.SGM 28MYN1 32040 Federal Register / Vol. 85, No. 103 / Thursday, May 28, 2020 / Notices Substances To Be Evaluated for Toxicological Profile Development Each year, ATSDR develops a list of substances to be considered for Toxicological Profile development. The nomination process includes consideration of all substances on ATSDR’s SPL, as well as other substances nominated by the public. For more information on ATSDR’s SPL, visit https://www.atsdr.cdc.gov/SPL/. Submission of nominations for Toxicological Profile development: Today’s notice invites voluntary public nominations for substances included on the SPL and for substances not listed on the SPL. When nominating a non-SPL substance, please include the rationale for the nomination. ATSDR will evaluate data and information associated with nominated substances and will determine the final list of substances to be chosen for Toxicological Profile development. Substances will be chosen according to ATSDR’s specific guidelines for selection. These guidelines can be found in the Selection Criteria, which may be accessed at www.atsdr.cdc.gov/ toxprofiles/guidance/ATSDR_TP_ Selection%20Criteria.pdf. Pamela I. Protzel Berman, Director, Office of Policy, Planning and Partnerships, Agency for Toxic Substances and Disease Registry. [FR Doc. 2020–11423 Filed 5–27–20; 8:45 am] BILLING CODE 4163–70–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2018–D–1398] Mitigation Strategies to Protect Food Against Intentional Adulteration; Draft Guidance for Industry; Extension of the Comment Period AGENCY: Food and Drug Administration, HHS. Notice of availability; extension of comment period ACTION: The Food and Drug Administration (FDA, we, or the Agency) is extending the comment period for the notice of availability that appeared in the Federal Register of February 14, 2020, entitled ‘‘Mitigation Strategies to Protect Food Against Intentional Adulteration; Draft Guidance for Industry.’’ This supplemental draft guidance document, when finalized, will help food facilities that manufacture, process, pack, or hold food, and that are required to register jbell on DSKJLSW7X2PROD with NOTICES SUMMARY: VerDate Sep<11>2014 16:32 May 27, 2020 Jkt 250001 to Protect Food Against Intentional Adulteration: Supplemental Draft Guidance for Industry.’’ Received comments will be placed in the docket and, except for those submitted as ‘‘Confidential Submissions,’’ publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday. • Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential Electronic Submissions with a heading or cover note that states ‘‘THIS DOCUMENT CONTAINS Submit electronic comments in the CONFIDENTIAL INFORMATION.’’ The following way: • Federal eRulemaking Portal: https:// Agency will review this copy, including the claimed confidential information, in www.regulations.gov. Follow the its consideration of comments. The instructions for submitting comments. second copy, which will have the Comments submitted electronically, claimed confidential information including attachments, to https:// redacted/blacked out, will be available www.regulations.gov will be posted to for public viewing and posted on the docket unchanged. Because your https://www.regulations.gov. Submit comment will be made public, you are solely responsible for ensuring that your both copies to the Dockets Management Staff. If you do not wish your name and comment does not include any contact information to be made publicly confidential information that you or a available, you can provide this third party may not wish to be posted, information on the cover sheet and not such as medical information, your or anyone else’s Social Security number, or in the body of your comments and you confidential business information, such must identify this information as ‘‘confidential.’’ Any information marked as a manufacturing process. Please note as ‘‘confidential’’ will not be disclosed that if you include your name, contact except in accordance with 21 CFR 10.20 information, or other information that and other applicable disclosure law. For identifies you in the body of your more information about FDA’s posting comments, that information will be of comments to public dockets, see 80 posted on https://www.regulations.gov. FR 56469, September 18, 2015, or access • If you want to submit a comment the information at: https:// with confidential information that you www.govinfo.gov/content/pkg/FR-2015do not wish to be made available to the 09-18/pdf/2015-23389.pdf. public, submit the comment as a Docket: For access to the docket to written/paper submission and in the read background documents or the manner detailed (see ‘‘Written/Paper electronic and written/paper comments Submissions’’ and ‘‘Instructions’’). received, go to https:// Written/Paper Submissions www.regulations.gov and insert the docket number, found in brackets in the Submit written/paper submissions as heading of this document, into the follows: ‘‘Search’’ box and follow the prompts • Mail/Hand Delivery/Courier (for and/or go to the Dockets Management written/paper submissions): Dockets Management Staff (HFA–305), Food and Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240–402–7500. Drug Administration, 5630 Fishers You may submit comments on any Lane, Rm. 1061, Rockville, MD 20852. guidance at any time (see 21 CFR • For written/paper comments 10.115(g)(5)). submitted to the Dockets Management Submit written requests for single Staff, FDA will post your comment, as copies of the guidance to the Center for well as any attachments, except for Food Safety and Applied Nutrition, information submitted, marked and Food and Drug Administration, 5001 identified, as confidential, if submitted Campus Dr., College Park, MD 20740. as detailed in ‘‘Instructions.’’ Instructions: All submissions received Send two self-addressed adhesive labels to assist that office in processing your must include the Docket No. FDA– requests. See the SUPPLEMENTARY 2018–D–1398 for ‘‘Mitigation Strategies under the Federal Food, Drug, and Cosmetic Act comply with the requirements of our regulation entitled ‘‘Mitigation Strategies to Protect Food Against Intentional Adulteration.’’ FDA is taking this action in response to a request for an extension to allow interested persons additional time to submit comments. DATES: FDA is extending the comment period on the notice of availability published February 14, 2020 (85 FR 8599). Submit either electronic or written comments on the supplemental draft guidance by August 14, 2020. ADDRESSES: You may submit comments on any guidance at any time as follows: PO 00000 Frm 00038 Fmt 4703 Sfmt 4703 E:\FR\FM\28MYN1.SGM 28MYN1

Agencies

[Federal Register Volume 85, Number 103 (Thursday, May 28, 2020)]
[Notices]
[Pages 32039-32040]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-11423]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Toxic Substances and Disease Registry

[Docket No. ATSDR-2020-0002]


Proposed Substances To Be Evaluated for Toxicological Profile 
Development

AGENCY: Agency for Toxic Substances and Disease Registry (ATSDR), 
Department of Health and Human Services (HHS).

ACTION: Request for comments on proposed substances to be evaluated for 
Toxicological Profile development.

-----------------------------------------------------------------------

SUMMARY: The Agency for Toxic Substances and Disease Registry (ATSDR) 
within the Department of Health and Human Services is initiating the 
development of another set of Toxicological Profiles. This notice 
solicits public nominations of substances for ATSDR to evaluate for 
Toxicological Profile development. ATSDR will consider nominations from 
the Substance Priority List (available at https://www.atsdr.cdc.gov/SPL/). ATSDR also accepts nominations for non-Comprehensive 
Environmental Response, Compensation, and Liability Act of 1980 
(CERCLA) substances that may have public health implications, on the 
basis of ATSDR's authority to prepare Toxicological Profiles for 
substances not found at sites on the CERCLA National Priorities List. 
For more information on the CERCLA National Priorities List, visit 
https://www.epa.gov/superfund/superfundnational-priorities-list-npl. 
The agency will do so in order to establish and maintain an inventory 
of literature, research, and studies on the health effects of toxic 
substances, to respond to requests for consultation, and to support the 
site-specific response actions conducted by ATSDR, as otherwise 
necessary.

DATES: Nominations from the Substance Priority List and/or additional 
substances must be received by June 29, 2020.

ADDRESSES: You may submit nominations, identified by Docket No. ATSDR-
2020-0002, by any of the following methods:
     Internet: Access the Federal eRulemaking portal at 
www.regulations.gov. Follow the instructions for submitting comments.
     Mail: Division of Toxicology and Human Health Sciences, 
Agency for Toxic Substances and Disease Registry, 1600 Clifton Rd. NE, 
Mail Stop S102-1, Atlanta, GA, 30329-4027. Attn: Docket No. ATSDR-2020-
0002.
    Instructions: All submissions must include the agency name and 
docket number for this notice. All relevant comments will be posted 
without change. This means that no confidential business information or 
other confidential information should be submitted in response to this 
notice. Refer to the section Submission of Nominations (below) for the 
specific information required.

FOR FURTHER INFORMATION CONTACT: For further information, please 
contact Susan Ingber, Agency for Toxic Substances and Disease Registry, 
Division of Toxicology and Human Health Sciences, 1600 Clifton Rd. NE, 
Mail Stop S102-1, Atlanta, GA, 30329-4027, Email: 
[email protected]; Phone: 1-800-232-4636.

SUPPLEMENTARY INFORMATION: The Superfund Amendments and Reauthorization 
Act of 1986 (SARA) [42 U.S.C. 9601 et seq.] amended the Comprehensive 
Environmental Response, Compensation, and Liability Act of 1980 (CERCLA 
or Superfund) [42 U.S.C. 9601 et seq.] by establishing certain 
requirements for ATSDR and the U.S. Environmental Protection Agency 
(EPA) with regard to hazardous substances most commonly found at 
facilities on the CERCLA National Priorities List (NPL) (for more 
information, visit https://www.epa.gov/superfund/superfund-nationalpriorities-list-npl). Among these statutory requirements is a 
mandate for the Administrator of ATSDR to prepare Toxicological 
Profiles for each substance included on the Priority List of Hazardous 
Substances (also known as the Substance Priority list (SPL)). This list 
identifies 275 hazardous substances found at NPL sites that ATSDR and 
EPA have determined pose the most significant current potential threat 
to human health.

[[Page 32040]]

Substances To Be Evaluated for Toxicological Profile Development

    Each year, ATSDR develops a list of substances to be considered for 
Toxicological Profile development. The nomination process includes 
consideration of all substances on ATSDR's SPL, as well as other 
substances nominated by the public. For more information on ATSDR's 
SPL, visit https://www.atsdr.cdc.gov/SPL/.
    Submission of nominations for Toxicological Profile development: 
Today's notice invites voluntary public nominations for substances 
included on the SPL and for substances not listed on the SPL. When 
nominating a non-SPL substance, please include the rationale for the 
nomination. ATSDR will evaluate data and information associated with 
nominated substances and will determine the final list of substances to 
be chosen for Toxicological Profile development. Substances will be 
chosen according to ATSDR's specific guidelines for selection. These 
guidelines can be found in the Selection Criteria, which may be 
accessed at www.atsdr.cdc.gov/toxprofiles/guidance/ATSDR_TP_Selection%20Criteria.pdf.

Pamela I. Protzel Berman,
Director, Office of Policy, Planning and Partnerships, Agency for Toxic 
Substances and Disease Registry.
[FR Doc. 2020-11423 Filed 5-27-20; 8:45 am]
BILLING CODE 4163-70-P